Gyroscope's lead investigational gene therapy, GT005, is being evaluated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.

It has received Fast Track designation from the US Food and Drug Administration and is being evaluated in Phase II clinical trials in two different genetically defined patient populations with GA.